Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Theocharis Panaretakis Image

      Theocharis Panaretakis, Ph.D.

      Department of Genitourinary Medical Oncology, Division of Cancer Medicine

      Present Title & Affiliation

      Primary Appointment

      Associate Professor, Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX

      Associate Professor, Institute of Environmental Medicine, Karolinska Institutet, Stockholm

      Dual/Joint/Adjunct Appointment

      Associate Professor, Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX

      Associate Professor, Institute of Environmental Medicine, Karolinska Institutet, Stockholm

      Education & Training

      Degree-Granting Education

      2003Karolinska Institutet, Solnavagen, US, Experimental Oncology, Ph.D
      1997University of Sussex, Falmer, GB, Biochemistry, BS

      Postgraduate Training

      2006-2008Research Fellowship, Institut Gustave Roussy, Villejuif
      2004-2006Research Fellowship, Karonliska Institutet, Stockholm

      Experience & Service

      Faculty Academic Appointments

      Visiting Associate Professor, Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2019

      Principal investigator, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 2010 - 2016

      Assistant Professor, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 2009

      Extramural Institutional Committee Activities

      Reviewer, Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2026 - Present

      Evaluator, Gyn Oncology & Reproductive Med Department, The University of Texas MD Anderson Cancer Center, 2026 - Present

      Reviewer, Academic Review Committee, MD Anderson Cancer Center, 2025 - Present

      Editorial Activities

      Section Editor, Cancers, 2019 - Present

      Editorial Board, Molecular and Cellular Oncology, 2014 - Present

      Section Advisory Board, Oncotarget, 2014 - Present

      Guest Associate Editor, Oncology, 2014

      Honors & Awards

      2025 - 2030PCF Tactical Award
      2015Strategy 2018, Karolinska Institutet
      2013Best Scientific Article, Karolinska Institutet
      2010 - 2011Future Academic Leaders, Karolinska Institutet
      2010Young Investigator Award, Swedish Cancer Society

      Professional Memberships

      AACR

      2023 - Present

      American Society of Clinical Oncology

      2018 - Present

      European Cell Death Organization Academy

      2015 - Present

      Selected Presentations & Talks

      Regional Presentations

      1. 2023. Extracellular Vesicles: Monitoring Molecular Changes on Acquisition of Resistance and Disease Progression. Conference. Extracellular Vesicles: Monitoring Molecular Changes on Acquisition of Resistance and Disease Progression, US.

      National Presentations

      1. 2017. Molecular Profiling of Liquid Biopsies from RA-223-treated Patients with Bone Metastatic CRPC reveals Differential Enrichment for Bone and Immune markers that Correlate with Overall Survival (poster). Conference. Molecular Profiling of Liquid Biopsies from RA-223-treated Patients with Bone Metastatic CRPC reveals Differential Enrichment for Bone and Immune markers that Correlate with Overall Survival (poster). San Francisco, CA, US.

      International Presentations

      1. 2018. Molecular Profiling of Bone Marrow or Plasma Exosomes for Predicting Therapy Response. Conference. Molecular Profiling of Bone Marrow or Plasma Exosomes for Predicting Therapy Response. Melbourne, AU.
      2. 2016. Prostate cancer-derived exosomes as predictors of response to therapy (poster). Conference. Prostate cancer-derived exosomes as predictors of response to therapy (poster). Rotterdam, NL.
      3. 2016. The role of anaplastic large cell lymphoma–derived exosomes in the tumor microenvironment (poster). Conference. The role of anaplastic large cell lymphoma–derived exosomes in the tumor microenvironment (poster). Rotterdam, NL.
      4. 2016. Energy-requiring uptake of prostasomes and PC3 cell-derived exosomes into nonmalignant and malignant cells (poster). Conference. Energy-requiring uptake of prostasomes and PC3 cell-derived exosomes into nonmalignant and malignant cells (poster). Rotterdam, NL.
      5. 2015. CMM Lecture: The X factor in Prostate Cancer. Conference. Center of Molecular Medicine. Stockholm, SE.
      6. 2014. Prostate cancer-derived exosomes: Biomarkers and Functional Properties. Conference. Prostate cancer-derived exosomes: Biomarkers and Functional Properties. Roserberg, SE.
      7. 2014. Prostate cancer-derived exosomes as predictors of response to therapy. Conference. Prostate cancer-derived exosomes as predictors of response to therapy. Rotterdam, NL.
      8. 2014. Proteomic analysis of exosomes from highly metastatic and non-metastatic murine breast cancer cell lines (poster). Conference. Proteomic analysis of exosomes from highly metastatic and non-metastatic murine breast cancer cell lines (poster). Rotterdam, NL.
      9. 2013. Discovery of novel prognostic and diagnostic biomarkers in cancer cell-derived vesicles. Conference. Discovery of novel prognostic and diagnostic biomarkers in cancer cell-derived vesicles. Uppsala, SE.
      10. 2012. Sorafenib Sorafenib Has Potent Antitumor Activity against Multiple Myeloma. Conference. Sorafenib Sorafenib Has Potent Antitumor Activity against Multiple Myeloma. Tallinn, EE.
      11. 2011. The EX factor in cancer therapy. Conference. The EX factor in cancer therapy. Lidingö, SE.

      Formal Peers

      1. 2017. Prostate cancer-derived exosomes: Biomarkers and Functional Properties. Visiting. Houston, TX, US.
      2. 2011. The X factor in Prostate Cancer. Invited. Djurönäset, SE.
      Read More
      Less

      Grant & Contract Support

      Date: 2026 - 2031
      Title:Prostate Cancer-Induced Bone Formation Regulates Immune Microenvironment in Prostate Cancer Bone Metastasis
      Funding Source:NIH
      Role:Co-I
      ID:FP29189
      Date: 2025 - 2028
      Title:Therapy Strategies to Overcome T Cell Insufficiency in the Bone-Tumor Microenvironment for Bone Metastasis
      Funding Source:DOD-PCRP
      Role:Co-I
      ID:PC240436
      Date: 2025 - 2030
      Title:Prostate Cancer-Induced Bone Formation Regulates Immune Microenvironment in Prostate Cancer Bone Metastasis
      Funding Source:NIH/NCI
      Role:Co-I
      ID:R01 CA278987-01A1
      Date: 2024 - 2026
      Title:Longitudinal Monitoring of Therapy-Induced Changes in “Extracellular Vesicle Bone Signature” and its Associations with Clinical Outcomes in Bone Metastatic Prostate Cancer
      Funding Source:MD Anderson-Ohio Health
      Role:PI
      Date: 2022 - 2023
      Title:Targeting prostate tumor-induced bone formation to reverse the immunosuppresive bone-TME and improve the efficacy of immune checkpoint therapies
      Funding Source:MD Anderson Moon Shot Program
      Role:Co-Program Leader
      Date: 2020 - 2021
      Title:Development of Rational Immunotherapy Combinations to Overcome the Immunosuppressive Prostate Tumor Microenvironment
      Funding Source:MD Anderson Moon Shot Program
      Role:Collaborator
      Date: 2019 - 2020
      Title:Prostate Cancer Moon Shot Flagship 2:Development of Rational Immunotherapy Combinations to Overcome the Immunosuppressive Prostate Tumor Microenvironment
      Funding Source:MD Anderson Moon Shot Program
      Role:Co-Leader
      Date: 2018 - 2019
      Title:Prostate Cancer Moonshot Flagship 1: Development of Mechanism-based Combination Therapies for Castration-Resistant Prostate Cancer Subproject: Targeting Prostate Cancer-Induced Aberrant Bone Formation for the Treatment of Bone Metastasis (S-H Lin)
      Funding Source:MD Anderson Moon Shot Program
      Role:Co-Leader
      Date: 2018 - 2025
      Title:Exosome Profiling of Immune and Non-Immune Bone Microenvironment to Improve Therapeutic Effect for Metastatic Prostate Cancer
      Funding Source:Cancerfonden (Swedish Cancer Society)
      Role:PI
      Date: 2017 - 2019
      Title:Impact of Local Therapy on Outcomes of Men with de novo Metastatic within Molecularly Defined Prostate Cancers
      Funding Source:Prostate Cancer Foundation
      Role:Co-PI
      ID:17Chal01
      Date: 2016 - 2020
      Title:Postgraduate Student Funds Prostate Cancer-Derived Exosomes as Predictors and Functional Modulators of Response to Therapy
      Funding Source:Karolinska Institutet
      Role:PI
      Date: 2015 - 2018
      Title:Exosome-based Prognostic Markers and Cancer Therapies
      Funding Source:Swedish Cancer Society (Cancerfonden)
      Role:PI
      Date: 2015 - 2017
      Title:Exosome-based Strategies to Discover Novel Biomarkers for Metastatic Prostate Cancer
      Funding Source:Radiumhemmets, Karolinska Institutet
      Role:PI

      Selected Publications

      Peer-Reviewed Articles

      1. Corn PG, Yu G, Fan Y, Zhang M, Troncoso P, Surasi DS, Liu S, Ajani JA, Logothetis CJ, Wang G, Panaretakis T, Lin SH. Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment. Prostate Cancer Prostatic Dis, 2025. e-Pub 2025. PMID: 41454189.
      2. Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis 28(3):802-808, 2025. e-Pub 2025. PMID: 39019979.
      3. Koutroumpakis E, Venkatesh N, Aparicio A, Song J, Panaretakis T, Deswal A, Logothetis CJ, Frigo DE, Hahn AW. Leptin levels are associated with coronary artery calcification in patients with advanced prostate cancer. Oncologist 30(8), 2025. e-Pub 2025. PMID: 39557398.
      4. Yu G, Corn PG, Mak CSL, Liang X, Zhang M, Troncoso P, Song JH, Lin SC, Song X, Liu J, Zhang J, Logothetis CJ, Melancon MP, Panaretakis T, Wang G, Lin SH. Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization. Proc Natl Acad Sci U S A 121(33):e2402903121, 2024. e-Pub 2024. PMID: 39102549.
      5. Pan T, Liu F, Hao X, Wang S, Wasi M, Song JH, Lewis VO, Lin PP, Moon B, Bird JE, Panaretakis T, Lin SH, Wu D, Farach-Carson MC, Wang L, Zhang N, An Z, Zhang XH, Satcher RL. BIGH3 mediates apoptosis and gap junction failure in osteocytes during renal cell carcinoma bone metastasis progression. Cancer Lett 596:217009, 2024. e-Pub 2024. PMID: 38849015.
      6. Lin SC, Yu G, Corn PG, Damasco J, Lee YC, Song JH, Navone NM, Logothetis CJ, Melancon MP, Panaretakis T, Lin SH. Radium-223 Treatment Produces Prolonged Suppression of Resident Osteoblasts and Decreased Bone Mineral Density in Trabecular Bone in Osteoblast Reporter Mice. Cancers (Basel) 16(14), 2024. e-Pub 2024. PMID: 39061241.
      7. Gentile E, Hahn AW, Song JH, Hoang A, Shepherd PDA, Ramachandran S, Navone NM, Efstathiou E, Titus M, Corn PG, Lin SH, Logothetis CJ, Panaretakis T. Monitoring Glucocorticoid Receptor in plasma derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun 3(12):2531-2543, 2023. e-Pub 2023. PMID: 37930121.
      8. Yu G, Corn PG, Mak CSL, Liang X, Zhang M, Troncoso P, Song JH, Lin SC, Song X, Liu J, Zhang J, Logothetis CJ, Melancon MP, Panaretakis T, Wang G, Lin SH. Prostate cancer-induced endothelial-to-osteoblast transition generates an immunosuppressive bone tumor microenvironment. bioRxiv, 2023. e-Pub 2023. PMID: 38076845.
      9. Gentile, E, Hahn, AW, Song, J, Hoang, A, Shepherd, P, Ramachandran, S, Navone, NM, Efstathiou, E, Titus, M, Corn, P, Lin, S, Logothetis, CJ, Panaretakis, T. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Research Communications 3(12):2531-2543, 2023. e-Pub 2023. PMID: 37930121.
      10. Sakellakis MJ, Hahn AW, Ramachandran S, Zhang M, Hoang A, Song JH, Liu J, Wang F, Basu HS, Sheperd P, Wang X, Frigo DE, Lin SH, Panaretakis T, Zhang J, Navone N, Troncoso P, Logothetis CJ, Titus MA. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer Prostatic Dis 26(4):751-758, 2023. e-Pub 2023. PMID: 36100698.
      11. Mourkioti I, Polyzou A, Veroutis D, Theocharous G, Lagopati N, Gentile E, Stravokefalou V, Thanos DF, Havaki S, Kletsas D, Panaretakis T, Logothetis CJ, Stellas D, Petty R, Blandino G, Papaspyropoulos A, Gorgoulis VG. A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer. J Exp Clin Cancer Res 42(1):187, 2023. e-Pub 2023. PMID: 37507762.
      12. Vardaki I, Özcan SS, Fonseca P, Lin SH, Logothetis CJ, Yachnin J, Ullen A, Panaretakis T. Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration resistant prostate cancer. Prostate 83(10):950-961, 2023. e-Pub 2023. PMID: 37074030.
      13. Lin, S, Yu, G, Lee, Y, Song, J, Song, X, Zhang, J, Panaretakis, T, Logothetis, CJ, Komatsu, Y, Yu-Lee, LY, Wang, G, Lin, S. Endothelial-to-osteoblast transition in normal mouse bone development. iScience 26(2), 2023. e-Pub 2023. PMID: 36798441.
      14. Yu G, Corn PG, Shen P, Song JH, Lee YC, Lin SC, Pan J, Agarwal SK, Panaretakis T, Pacifici M, Logothetis CJ, Yu-Lee LY, Lin SH. Retinoic acid receptor activation reduces metastatic prostate cancer bone lesions by blocking the endothelial-to-osteoblast transition. Cancer Res 82(17):3158-3171, 2022. e-Pub 2022. PMID: 35802768.
      15. Chioureas D, Beck J, Baltatzis G, Vardaki I, Fonseca P, Tsesmetzis N, Vega F, Leventaki V, Eliopoulos AG, Drakos E, Rassidakis GZ, Panaretakis T. ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment. Cancers (Basel) 14(12), 2022. e-Pub 2022. PMID: 35740600.
      16. Lee YC, Lin SC, Yu G, Zhu M, Song JH, Rivera K, Pappin DJ, Logothetis CJ, Panaretakis T, Wang G, Yu-Lee LY, Lin SH. Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition. Oncogene 41(6):757-769, 2022. e-Pub 2022. PMID: 34845375.
      17. Pan T, Lin SC, Lee YC, Yu G, Song JH, Pan J, Titus M, Satcher RL, Panaretakis T, Logothetis C, Yu-Lee LY, Lin SH. Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone. Oncogene 40(27):4592-4603, 2021. e-Pub 2021. PMID: 34127814.
      18. Vardaki I, Corn P, Gentile E, Song JH, Madan N, Hoang A, Parikh N, Guerra L, Lee YC, Lin SC, Yu G, Santos E, Melancon MP, Troncoso P, Navone N, Gallick GE, Efstathiou E, Subudhi SK, Lin SH, Logothetis CJ, Panaretakis T. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res 27(11):3253-3264, 2021. e-Pub 2021. PMID: 33753455.
      19. Yu G, Shen P, Lee YC, Pan J, Song JH, Pan T, Lin SC, Liang X, Wang G, Panaretakis T, Logothetis CJ, Gallick GE, Yu-Lee LY, Lin SH. Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4. iScience 24(4):102388, 2021. e-Pub 2021. PMID: 33981975.
      20. Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clin Cancer Res 26(5):990-999, 2020. e-Pub 2020. PMID: 31941830.
      21. Koinis F, Corn P, Parikh N, Song J, Vardaki I, Mourkioti I, Lin SH, Logothetis C, Panaretakis T, Gallick G. Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer. Cancers (Basel) 12(1), 2020. e-Pub 2020. PMID: 31963871.
      22. Yachnin J, Gilje B, Thon K, Johansson H, Brandberg Y, Panaretakis T, Ullén A. Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab). Eur J Cancer 97:33-40, 2018. e-Pub 2018. PMID: 29685343.
      23. Forsberg J, Li X, Zamaraev AV, Panaretakis T, Zhivotovsky B, Olsson M. Caspase-2 associates with FAN through direct interaction and overlapping functionality. Biochem Biophys Res Commun 499(4):822-828, 2018. e-Pub 2018. PMID: 29621545.
      24. Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia 31(7):1633-1637, 2017. e-Pub 2017. PMID: 28344319.
      25. Kharaziha P, Panaretakis T. Dynamics of Atg5-Atg12-Atg16L1 Aggregation and Deaggregation. Methods Enzymol 587:247-255, 2017. e-Pub 2017. PMID: 28253959.
      26. Pathan M, Keerthikumar S, Chisanga D, Alessandro R, Ang CS, Askenase P, Batagov AO, Benito-Martin A, Camussi G, Clayton A, Collino F, Di Vizio D, Falcon-Perez JM, Fonseca P, Fonseka P, Fontana S, Gho YS, Hendrix A, Hoen EN, Iraci N, Kastaniegaard K, Kislinger T, Kowal J, Kurochkin IV, Leonardi T, Liang Y, Llorente A, Lunavat TR, Maji S, Monteleone F, Øverbye A, Panaretakis T, Patel T, Peinado H, Pluchino S, Principe S, Ronquist G, Royo F, Sahoo S, Spinelli C, Stensballe A, Théry C, van Herwijnen MJC, Wauben M, Welton JL, Zhao K, Mathivanan S. A novel community driven software for functional enrichment analysis of extracellular vesicles data. J Extracell Vesicles 6(1):1321455, 2017. e-Pub 2017. PMID: 28717418.
      27. Vardaki I, Sanchez C, Fonseca P, Olsson M, Chioureas D, Rassidakis G, Ullén A, Zhivotovsky B, Björkholm M, Panaretakis T. Caspase-3-dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells. Blood 128(23):2655-2665, 2016. e-Pub 2016. PMID: 27742710.
      28. Vardaki I, Ceder S, Rutishauser D, Baltatzis G, Foukakis T, Panaretakis T. Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes. Oncotarget 7(46):74966-74978, 2016. e-Pub 2016. PMID: 27589561.
      29. Ronquist KG, Sanchez C, Dubois L, Chioureas D, Fonseca P, Larsson A, Ullén A, Yachnin J, Ronquist G, Panaretakis T. Energy-requiring uptake of prostasomes and PC3 cell-derived exosomes into non-malignant and malignant cells. J Extracell Vesicles 5:29877, 2016. e-Pub 2016. PMID: 26955882.
      30. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bánhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolomé A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, Bédard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Bénard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Böckler S, Boes M, Boesze-Battaglia. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. e-Pub 2016. PMID: 26799652.
      31. Kharaziha P, Chioureas D, Baltatzis G, Fonseca P, Rodriguez P, Gogvadze V, Lennartsson L, Björklund AC, Zhivotovsky B, Grandér D, Egevad L, Nilsson S, Panaretakis T. Sorafenib-induced defective autophagy promotes cell death by necroptosis. Oncotarget 6(35):37066-82, 2015. e-Pub 2015. PMID: 26416459.
      32. Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullén A, Yachnin J, Nilsson S, Panaretakis T. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget 6(25):21740-54, 2015. e-Pub 2015. PMID: 25844599.
      33. Dubois L, Stridsberg M, Kharaziha P, Chioureas D, Meersman N, Panaretakis T, Ronquist KG. Malignant cell-derived extracellular vesicles express different chromogranin epitopes compared to prostasomes. Prostate 75(10):1063-73, 2015. e-Pub 2015. PMID: 25783430.
      34. Kharaziha P, Ceder S, Sanchez C, Panaretakis T. Multitargeted therapies for multiple myeloma. Autophagy 9(2):255-7, 2013. e-Pub 2013. PMID: 23183549.
      35. Rundqvist H, Augsten M, Strömberg A, Rullman E, Mijwel S, Kharaziha P, Panaretakis T, Gustafsson T, Östman A. Effect of acute exercise on prostate cancer cell growth. PLoS One 8(7):e67579, 2013. e-Pub 2013. PMID: 23861774.
      36. Kharaziha P, De Raeve H, Fristedt C, Li Q, Gruber A, Johnsson P, Kokaraki G, Panzar M, Laane E, Osterborg A, Zhivotovsky B, Jernberg-Wiklund H, Grandér D, Celsing F, Björkholm M, Vanderkerken K, Panaretakis T. Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. Cancer Res 72(20):5348-62, 2012. e-Pub 2012. PMID: 22952216.
      37. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Cho. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544, 2012. e-Pub 2012. PMID: 22966490.
      38. Kharaziha P, Rodriguez P, Li Q, Rundqvist H, Björklund AC, Augsten M, Ullén A, Egevad L, Wiklund P, Nilsson S, Kroemer G, Grander D, Panaretakis T. Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell Death Dis 3:e262, 2012. e-Pub 2012. PMID: 22278289.
      39. Wemeau M, Kepp O, Tesnière A, Panaretakis T, Flament C, De Botton S, Zitvogel L, Kroemer G, Chaput N. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 1:e104, 2010. e-Pub 2010. PMID: 21368877.
      40. Kepp O, Gdoura A, Martins I, Panaretakis T, Schlemmer F, Tesniere A, Fimia GM, Ciccosanti F, Burgevin A, Piacentini M, Eggleton P, Young PJ, Zitvogel L, van Endert P, Kroemer G. Lysyl tRNA synthetase is required for the translocation of calreticulin to the cell surface in immunogenic death. Cell Cycle 9(15):3072-7, 2010. e-Pub 2010. PMID: 20699648.
      41. Ullén A, Farnebo M, Thyrell L, Mahmoudi S, Kharaziha P, Lennartsson L, Grandér D, Panaretakis T, Nilsson S. Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int J Oncol 37(1):15-20, 2010. e-Pub 2010. PMID: 20514392.
      42. Grandér D, Kharaziha P, Laane E, Pokrovskaja K, Panaretakis T. Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies. Autophagy 5(8):1198-200, 2009. e-Pub 2009. PMID: 19855186.
      43. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Génin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, André F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15(10):1170-8, 2009. e-Pub 2009. PMID: 19767732.
      44. Laane E, Tamm KP, Buentke E, Ito K, Kharaziha P, Khahariza P, Oscarsson J, Corcoran M, Björklund AC, Hultenby K, Lundin J, Heyman M, Söderhäll S, Mazur J, Porwit A, Pandolfi PP, Zhivotovsky B, Panaretakis T, Grandér D. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ 16(7):1018-29, 2009. e-Pub 2009. PMID: 19390558.
      45. Hernlund E, Kutuk O, Basaga H, Linder S, Panaretakis T, Shoshan M. Cisplatin-induced nitrosylation of p53 prevents its mitochondrial translocation. Free Radic Biol Med 46(12):1607-13, 2009. e-Pub 2009. PMID: 19328230.
      46. Ehnfors J, Kost-Alimova M, Persson NL, Bergsmedh A, Castro J, Levchenko-Tegnebratt T, Yang L, Panaretakis T, Holmgren L. Horizontal transfer of tumor DNA to endothelial cells in vivo. Cell Death Differ 16(5):749-57, 2009. e-Pub 2009. PMID: 19219067.
      47. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, Yuan J, Zitvogel L, Madeo F, Williams DB, Kroemer G. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28(5):578-90, 2009. e-Pub 2009. PMID: 19165151.
      48. Madeo F, Durchschlag M, Kepp O, Panaretakis T, Zitvogel L, Fröhlich KU, Kroemer G. Phylogenetic conservation of the preapoptotic calreticulin exposure pathway from yeast to mammals. Cell Cycle 8(4):639-42, 2009. e-Pub 2009. PMID: 19182525.
      49. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, van Endert P, Zitvogel L, Madeo F, Kroemer G. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 15(9):1499-509, 2008. e-Pub 2008. PMID: 18464797.
      50. Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, Panaretakis T, Shoshan MC. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 123(2):476-483, 2008. e-Pub 2008. PMID: 18452174.
      51. Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, Panaretakis T, Siemeister G, Lage H, Nanty L, Hammer S, Mittelstaedt K, Winsel S, Eschenbrenner J, Castedo M, Demarche C, Klar U, Kroemer G. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 68(13):5301-8, 2008. e-Pub 2008. PMID: 18593931.
      52. Tufi R, Panaretakis T, Bianchi K, Criollo A, Fazi B, Di Sano F, Tesniere A, Kepp O, Paterlini-Brechot P, Zitvogel L, Piacentini M, Szabadkai G, Kroemer G. Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ 15(2):274-82, 2008. e-Pub 2008. PMID: 18034188.
      53. Panaretakis T, Hjortsberg L, Tamm KP, Björklund AC, Joseph B, Grandér D. Interferon alpha induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin. Mol Biol Cell 19(1):41-50, 2008. e-Pub 2008. PMID: 17942603.
      54. Laane E, Panaretakis T, Pokrovskaja K, Buentke E, Corcoran M, Söderhäll S, Heyman M, Mazur J, Zhivotovsky B, Porwit A, Grandér D. Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members. Haematologica 92(11):1460-9, 2007. e-Pub 2007. PMID: 18024393.
      55. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L, Kroemer G. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 14(10):1848-50, 2007. e-Pub 2007. PMID: 17657249.
      56. Berndtsson M, Hägg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 120(1):175-80, 2007. e-Pub 2007. PMID: 17044026.
      57. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54-61, 2007. e-Pub 2007. PMID: 17187072.
      58. Ihrlund LS, Hernlund E, Viktorsson K, Panaretakis T, Barna G, Sabapathy K, Linder S, Shoshan MC. Two distinct steps of Bak regulation during apoptotic stress signaling: different roles of MEKK1 and JNK1. Exp Cell Res 312(9):1581-9, 2006. e-Pub 2006. PMID: 16529740.
      59. Panaretakis T, Laane E, Pokrovskaja K, Björklund AC, Moustakas A, Zhivotovsky B, Heyman M, Shoshan MC, Grandér D. Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. Mol Biol Cell 16(8):3821-31, 2005. e-Pub 2005. PMID: 15917298.
      60. Thyrell L, Hjortsberg L, Arulampalam V, Panaretakis T, Uhles S, Dagnell M, Zhivotovsky B, Leibiger I, Grandér D, Pokrovskaja K. Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem 279(23):24152-62, 2004. e-Pub 2004. PMID: 15056668.
      61. Panaretakis T, Pokrovskaja K, Shoshan MC, Grandér D. Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene 22(29):4543-56, 2003. e-Pub 2003. PMID: 12881711.
      62. Panaretakis T, Pokrovskaja K, Shoshan MC, Grandér D. Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem 277(46):44317-26, 2002. e-Pub 2002. PMID: 12193597.
      63. Zvyagilskaya R, Parchomenko O, Abramova N, Allard P, Panaretakis T, Pattison-Granberg J, Persson BL. Proton- and sodium-coupled phosphate transport systems and energy status of Yarrowia lipolytica cells grown in acidic and alkaline conditions. J Membr Biol 183(1):39-50, 2001. e-Pub 2001. PMID: 11547351.
      64. Panaretakis T, Shabalina IG, Grandér D, Shoshan MC, DePierre JW. Reactive oxygen species and mitochondria mediate the induction of apoptosis in human hepatoma HepG2 cells by the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid. Toxicol Appl Pharmacol 173(1):56-64, 2001. e-Pub 2001. PMID: 11350215.
      65. Shabalina IG, Panaretakis T, Bergstrand A, DePierre JW. Effects of the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid, on apoptosis in human hepatoma HepG2 cells. Carcinogenesis 20(12):2237-46, 1999. e-Pub 1999. PMID: 10590214.

      Invited Articles

      1. Panaretakis T. Cisplatin-induced apoptosis and development of resistance are transcriptionally distinct processes. Cell Cycle 11(20):3723, 2012. e-Pub 2012. PMID: 22983001.
      2. Panaretakis T, Joseph B, Zhivotovsky B. Back to Stockholm for 'metabolism, epigenetics and cell death. Cell Death Differ 19(5):909-12, 2012. e-Pub 2012. PMID: 22301918.
      3. Panaretakis T, Hjortsberg L, Lambert JM, Joseph B. Second Cell Death Network symposium: the vital cell death. Cell Death Differ 16(9):1300-02, 2009. e-Pub 2009. PMID: 19684639.

      Review Articles

      1. Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, Agostini M, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Aqeilan RI, Arama E, Baehrecke EH, Balachandran S, Bano D, Barlev NA, Bartek J, Bazan NG, Becker C, Bernassola F, Bertrand MJM, Bianchi ME, Blagosklonny MV, Blander JM, Blandino G, Blomgren K, Borner C, Bortner CD, Bove P, Boya P, Brenner C, Broz P, Brunner T, Damgaard RB, Calin GA, Campanella M, Candi E, Carbone M, Carmona-Gutierrez D, Cecconi F, Chan FK, Chen GQ, Chen Q, Chen YH, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Ciliberto G, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Daugaard M, Dawson TM, Dawson VL, De Maria R, De Strooper B, Debatin KM, Deberardinis RJ, Degterev A, Del Sal G, Deshmukh M, Di Virgilio F, Diederich M, Dixon SJ, Dynlacht BD, El-Deiry WS, Elrod JW, Engeland K, Fimia GM, Galassi C, Ganini C, Garcia-Saez AJ, Garg AD, Garrido C, Gavathiotis E, Gerlic M, Ghosh S, Green DR, Greene LA, Gronemeyer H, Häcker G, Hajnóczky G, Hardwick JM, Haupt Y, He S, Heery DM, Hengartner MO, Hetz C, Hildeman DA, Ichijo H, Inoue S, Jäättelä M, Janic A, Joseph B, Jost PJ, Kanneganti TD, Karin M, Kashkar H, Kaufmann T, Kelly GL, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Kluck R, Krysko DV, Kulms D, Kumar S, Lavandero S, Lavrik IN, Lemasters JJ, Liccardi G, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Luedde T, MacFarlane M, Madeo F, Malorni W, Manic G, Mantovani R, Marchi S, Marine JC, Martin SJ, Martinou JC, Mastroberardino PG, Medema JP, Mehlen P, Meier P, Melino G, Melino S, Miao EA, Moll UM, Muñoz-Pinedo C, Murphy DJ, Niklison-Chirou MV, Novelli F, Núñez G, Oberst A, Ofengeim D, Opferman JT, Oren M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pentimalli F, Pereira DM, Pervaiz S, Peter ME, Pinton P, Porta G, Prehn JHM, Puthalakath H, Rabinovich GA, Rajalingam K, Ravichandran KS, Rehm M, Ricci JE, Rizzuto R, Robinson N, Rodrigues CMP, Rotblat B, Rothlin CV, Rubinsztein DC, Rudel T, Rufini A, R. Apoptotic cell death in disease-Current understanding of the NCCD 2023. Cell Death Differ 30(5):1097-1154, 2023. e-Pub 2023. PMID: 37100955.
      2. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25(3):486-541, 2018. e-Pub 2018. PMID: 29362479.
      3. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 22(1):58-73, 2015. e-Pub 2015. PMID: 25236395.
      4. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fucíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3(9):e955691, 2014. e-Pub 2014. PMID: 25941621.
      5. Kharaziha P, Ceder S, Li Q, Panaretakis T. Tumor cell-derived exosomes: a message in a bottle. Biochim Biophys Acta 1826(1):103-11, 2012. e-Pub 2012. PMID: 22503823.
      6. Grandér D, Panaretakis T. Autophagy: cancer therapy's friend or foe?. Future Med Chem 2(2):285-97, 2010. e-Pub 2010. PMID: 21426194.
      7. Kepp O, Senovilla L, Galluzzi L, Panaretakis T, Tesniere A, Schlemmer F, Madeo F, Zitvogel L, Kroemer G. Viral subversion of immunogenic cell death. Cell Cycle 8(6):860-9, 2009. e-Pub 2009. PMID: 19221507.
      8. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, Kroemer G. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 20(5):504-11, 2008. e-Pub 2008. PMID: 18573340.
      9. Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 14(4):141-51, 2008. e-Pub 2008. PMID: 18353726.
      10. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 15(1):3-12, 2008. e-Pub 2008. PMID: 18007663.
      11. Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P, Ghiringhelli F, Apetoh L, Chaput N, Flament C, Ullrich E, de Botton S, Zitvogel L, Kroemer G. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev 220:22-34, 2007. e-Pub 2007. PMID: 17979837.
      12. Chaput N, De Botton S, Obeid M, Apetoh L, Ghiringhelli F, Panaretakis T, Flament C, Zitvogel L, Kroemer G. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med (Berl) 85(10):1069-76, 2007. e-Pub 2007. PMID: 17891368.
      13. Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res 67(17):7941-4, 2007. e-Pub 2007. PMID: 17804698.
      14. Pokrovskaja K, Panaretakis T, Grandér D. Alternative signaling pathways regulating type I interferon-induced apoptosis. J Interferon Cytokine Res 25(12):799-810, 2005. e-Pub 2005. PMID: 16375608.

      Book Chapters

      1. Fonseca P, Vardaki I, Occhionero A, Panaretakis T. Chapter Five: Metabolic and Signaling Functions of Cancer Cell-Derived Extracellular Vesicles. In: International Review of Cell and Molecular Biology. Elsevier, 175-199, 2016.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top